1-12 of 12
Silja Mack
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Clinical Trials & Observations
Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Dirk Winkler, Eugen Tausch, Patrick Hoth, Jennifer Edelmann, Daniel Mertens, Lars Bullinger, Manuela Bergmann, Sabrina Kless, Silja Mack, Ulrich Jäger, Nancy Patten, Lin Wu, Michael K. Wenger, Günter Fingerle-Rowson, Peter Lichter, Mario Cazzola, Clemens M. Wendtner, Anna M. Fink, Kirsten Fischer, Raymonde Busch, Michael Hallek, Hartmut Döhner
Journal: Blood
Blood (2014) 123 (21): 3247–3254.
https://doi.org/10.1182/blood-2014-01-546150
Published: 2014
Includes: Supplemental data
Journal Articles

Pomalidomide In MPN–associated Myelofibrosis With Cytopenia: Results Of The Mpnsg 01-09 Study

Richard F. Schlenk, MD, Frank Stegelmann, MD, Andreas Reiter, MD, Edgar Jost, MD, Norbert Gattermann, MD, Holger Hebart, Cornelius F. Waller, MD, Andreas Hochhaus, MD, Uwe Platzbecker, MD, PhD, Philippe Schafhausen, MD, Igor W. Blau, MD, Walter Verbeek, MD, Florian H Heidel, MD, Martin Werner, MD, Hans Kreipe, MD, Cora Heiligensetzer, Silja Mack, MSc, Sabine Ostlender, Veronica Teleanu, MD, Axel Benner, Hartmut Döhner, MD, Martin Grießhammer, M.D., Konstanze Döhner, MD
Journal: Blood
Blood (2013) 122 (21): 2822.
https://doi.org/10.1182/blood.V122.21.2822.2822
Published: 2013
Journal Articles

NOTCH1 , SF3B1 , and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

Brief Report
Andrea Schnaiter, Peter Paschka, Marianna Rossi, Thorsten Zenz, Andreas Bühler, Dirk Winkler, Mario Cazzola, Konstanze Döhner, Jennifer Edelmann, Daniel Mertens, Sabrina Kless, Silja Mack, Raymonde Busch, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood
Blood (2013) 122 (7): 1266–1270.
https://doi.org/10.1182/blood-2013-03-488197
Published: 2013
Includes: Supplemental data
Journal Articles

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW

Stephan Stilgenbauer, MD, Florence Cymbalista, MD, PhD, Veronique Leblond, Alain Delmer, MD, Silja Mack, MSc, Andreas Bühler, Dirk Winkler, Thorsten Zenz, MD, Raymonde Busch, Stefan Ibach, Sylvain Choquet, MD, Dartigeas Caroline, Bruno Cazin, Dr., Olivier Tournilhac, MD, PhD, Till M Seiler, MD, Katja Zirlik, Jürgen Alt, MD, Martin Sökler, MD, Johannes Schetelig, MD, Peter Dreger, MD, Michael Hallek, MD, Hartmut Döhner, MD
Journal: Blood
Blood (2012) 120 (21): 716.
https://doi.org/10.1182/blood.V120.21.716.716
Published: 2012
Journal Articles

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Stephan Stilgenbauer, MD, Raymonde Busch, Andrea Schnaiter, MD, Peter Paschka, Marianna Rossi, Konstanze Döhner, Thorsten Zenz, MD, Andreas Bühler, Dirk Winkler, Jennifer Edelmann, MD, Daniel Mertens, PhD, Lars Bullinger, MD, PhD, Sabrina Kless, Silja Mack, MSc, Sebastian Böttcher, MD, Matthias Ritgen, Michael Kneba, MD, PhD, Ulrich Jäger, MD, Peter Lichter, Nancy Patten, PhD., Michael K. Wenger, Myriam Mendila, MD, Gunter Fingerle-Rowson, MD, PhD, Mario Cazzola, Clemens Wendtner, Anna Maria Fink, MD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner
Journal: Blood
Blood (2012) 120 (21): 433.
https://doi.org/10.1182/blood.V120.21.433.433
Published: 2012
Journal Articles

NOTCH1, SF3B1 and TP53 Mutations in Fludarabine-Refractory CLL Patients Treated with Alemtuzumab: Results From the CLL2H Trial of the Gcllsg

Andrea Schnaiter, MD, Marianna Rossi, Peter Paschka, Mario Cazzola, Konstanze Döhner, MD, Jennifer Edelmann, MD, Andreas Bühler, MD, Sabrina Kless, Daniel Mertens, PhD, Raymonde Busch, Silja Mack, MSc, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2012) 120 (21): 710.
https://doi.org/10.1182/blood.V120.21.710.710
Published: 2012
Journal Articles

Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.

Johannes Bloehdorn, MD, Martin Sill, PhD, Andreas Bühler, MD, Silja Mack, MSc, Doris Winter, Lars Bullinger, MD, PhD, Arefeh Rouhi, PhD, Florian Kuchenbauer, MD, PhD, Daniel Mertens, PhD, Axel Benner, Dipl.Stat., Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2012) 120 (21): 2874.
https://doi.org/10.1182/blood.V120.21.2874.2874
Published: 2012
Journal Articles

Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01–09 Study (ClinicalTrials.gov Identifier: NCT00949364).

Richard F Schlenk, MD, Andreas Reiter, MD, Norbert Gattermann, MD, Holger Hebart, Edgar Jost, MD, Uwe Platzbecker, MD, Andreas Hochhaus, MD, Cornelius F. Waller, MD, Philippe Schafhausen, Igor W. Blau, MD, Walter Verbeek, MD, Martin Werner, MD, Hans H. Kreipe, MD, Carolin Mahler, Silja Mack, MSc, Stefanie Schauer, Sabine Ostlender, Frank Stegelmann, MD, Axel Benner, Dipl.Stat., Martin Griesshammer, MD, Konstanze Döhner, MD
Journal: Blood
Blood (2012) 120 (21): 2840.
https://doi.org/10.1182/blood.V120.21.2840.2840
Published: 2012
Journal Articles

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW

Stephan Stilgenbauer, Prof. Dr. med, Florence Cymbalista, Pr, Véronique Leblond, Pr, Alain Delmer, MD, Dirk Winkler, MD, Andreas Bühler, Dr. med., Thorsten Zenz, Prof. Dr. med., Silja Mack, Raymonde Busch, Dipl.-Math., Axel Hinke, Dr., Sylvain Choquet, MD, Caroline Dartigeas, Dr., Bruno Cazin, Dr., Olivier Tournilhac, MD, PhD, Michael Rieger, MD, Jürgen Alt, Dr. med, Martin Sökler, Dr. med, Johannes Schetelig, MD, Peter Dreger, Prof. Dr. med., Michael Hallek, MD, Hartmut Döhner, Prof. Dr. med.
Journal: Blood
Blood (2011) 118 (21): 2854.
https://doi.org/10.1182/blood.V118.21.2854.2854
Published: 2011
Journal Articles

Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine – Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW

Stephan Stilgenbauer, M.D., Florence Cymbalista, Véronique Leblond, Alain Delmer, MD, Thorsten Zenz, MD, Dirk Winkler, Andreas Bühler, Silja Mack, Raymonde Busch, Stefan Ibach, Sylvain Choquet, MD, Caroline Dartigeas, Bruno Cazin, MD, Olivier Tournilhac, MD, PhD, Michael Rieger, Martin Sökler, Till Seiler, Johannes Schetelig, Peter Dreger, MD, PhD, Michael Hallek, MD, Hartmut Döhner, MD
Journal: Blood
Blood (2010) 116 (21): 920.
https://doi.org/10.1182/blood.V116.21.920.920
Published: 2010
Journal Articles

Prospective Phase III Trial of Valproic acid (VPA) In Combination with All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy for AML In Older Patients: The German-Austrian AMLSG 06-04 Study

Michela Tassara, eronika Hofer, V, Konstanze Döhner, Marie Lilienfeld-Toal, Gerhard Held, MD, Katharina Götze, Heinz A. Horst, MD, PhD, Sibylla Wilhelm, MD, Stephan Kremers, CA, MD, Elisabeth Koller, Daniela Späth, Silja Mack, Carina Morlok, Martin Göttlicher, Hartmut Döhner, MD, Richard F. Schlenk, MD
Journal: Blood
Blood (2010) 116 (21): 185.
https://doi.org/10.1182/blood.V116.21.185.185
Published: 2010
Journal Articles

Induction Therapy with Idarubicin and Etoposide Combined with Sequential or Concurrent Azacitidine In Patients with High-Risk Acute Myeloid Leukemia: Pilot-Phase of the AMLSG 12-09 Study

Frank G. Rücker, Stephan Stilgenbauer, M.D., Martin Bommer, Daniela Späth, Silja Mack, Konstanze Döhner, Hartmut Döhner, MD, Richard F. Schlenk, MD
Journal: Blood
Blood (2010) 116 (21): 2184.
https://doi.org/10.1182/blood.V116.21.2184.2184
Published: 2010